NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Upgraded by Zacks Research

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other research firms also recently issued reports on NRXP. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, November 3rd. BTIG Research lifted their target price on NRx Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, November 11th. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. Wolfe Research started coverage on shares of NRx Pharmaceuticals in a report on Thursday, October 15th. They issued an “outperform” rating for the company. Finally, UBS Group reissued a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 26th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Read Our Latest Report on NRXP

NRx Pharmaceuticals Stock Up 14.0%

NASDAQ NRXP opened at $2.45 on Monday. The company has a market cap of $106.94 million, a PE ratio of -7.21 and a beta of 2.11. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The firm’s 50-day simple moving average is $2.77 and its two-hundred day simple moving average is $2.97.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.16. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.28 million. As a group, equities research analysts anticipate that NRx Pharmaceuticals will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC bought a new position in shares of NRx Pharmaceuticals in the second quarter worth approximately $54,000. SBI Securities Co. Ltd. lifted its position in NRx Pharmaceuticals by 292.1% during the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock valued at $58,000 after purchasing an additional 14,900 shares during the last quarter. Prime Capital Investment Advisors LLC bought a new stake in NRx Pharmaceuticals during the third quarter valued at approximately $364,000. Commonwealth Equity Services LLC grew its stake in NRx Pharmaceuticals by 30.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock worth $1,725,000 after buying an additional 136,350 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in NRx Pharmaceuticals by 411.4% in the 3rd quarter. Marshall Wace LLP now owns 995,172 shares of the company’s stock worth $2,906,000 after buying an additional 800,592 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

Top NRx Pharmaceuticals Stories

Investors following NRXP have been watching these stories:

  • Positive Sentiment: NRx is targeting a rolling NDA submission for NRX-100 by year-end, with a Yale collaboration intended to support its accelerated-approval pathway. It also announced NRX-200, a subcutaneous ketamine candidate, and an $11.25 million DARPA contract to fund a Phase 3 NRX-101 trial. NRx outlines ketamine market and NRX-100 target
  • Neutral Sentiment: Q3 revenue rose to about $1.2 million from $0.2 million a year earlier, and the $0.05-per-share loss was narrower than analyst expectations. However, revenue was below estimates. NRx Q3 results
  • Negative Sentiment: Operating loss widened to $8.1 million from $4.0 million year over year, largely amid higher selling and administrative costs tied to the launch. NRx reported $19.8 million in cash at quarter-end, making commercial execution and cash use important risks to monitor. NRx Q3 results and corporate update

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

Featured Stories

Analyst Recommendations for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.